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Islet β-cell replacement and regeneration are two promising approaches for the treatment of Type 1 Diabetes Mellitus. Indeed,
the success of islet transplantation in normalizing blood glucose in diabetic patients has provided the proof of principle that
cell replacement can be employed as a safe and eﬃcacious treatment. Nonetheless, shortage of organ donors has hampered
expansion of this approach. Alternative sources of insulin-producing cells are mandatory to fill this gap. Although great advances
have been achieved in generating surrogate β-cells from stem cells, current protocols have yet to produce functionally mature
insulin-secreting cells. Recently, the concept of islet regeneration in which new β-cells are formed from either residual β-cell
proliferation or transdiﬀerentiation of other endocrine islet cells has gained much interest as an attractive therapeutic alternative
to restore β-cell mass. Complementary approaches to cell replacement and regeneration could aim at enhancing β-cell survival and
function. Herein, we discuss the value of Hepatocyte Growth Factor (HGF), Glucose-Dependent Insulinotropic Peptide (GIP),
Paired box gene 4 (Pax4) and Liver Receptor Homolog-1 (LRH-1) as key players for β-cell replacement and regeneration therapies.
These factors convey β-cell protection and enhanced function as well as facilitating proliferation and transdiﬀerentiation of other
pancreatic cell types to β-cells, under stressful conditions.
1. Diabetes Mellitus and β-Cell Regeneration
The global incidence of Diabetes Mellitus (DM) has
increased alarmingly in the past ten years, becoming one
of the most common chronic diseases. It is estimated
that this disorder will aﬀect 552 million people by 2030
(http://www.idf.org/media-events/press-releases/2011/diab-
etes-atlas-5th-edition). Changing lifestyle leading to reduced
physical activity and increased obesity has been pointed
as the major culprit for this increase. DM is a group of
metabolic diseases characterized by hyperglycemia due to
defects in insulin secretion by pancreatic β-cells, insulin
action on target tissues, or both [1]. Based on its etiology,
DM has been classified into four main groups [1]; (1) Type 1
DM (T1DM) that results from lack of insulin production due
to selective autoimmune destruction of pancreatic β-cells;
(2) Type 2 DM (T2DM) caused by a combination of insulin
resistance in the main target tissues (liver, muscle, and fat)
and inadequate compensatory insulin secretion response by
β-cells; (3) other specific type of diabetes which includes the
genetic defects of the β-cell; (4) gestational diabetes mellitus
(GDM), characterized by glucose intolerance with onset or
first recognition during pregnancy.
Existing treatments for T1DM and long-term T2DM
patients are primarily focused on insulin supplementation.
However, despite the beneficial eﬀects of insulin therapy
on glucose homeostasis, poor patient implementation often
leads to diabetic complications such as retinopathy and
nephropathy as well as cardiovascular and cerebrovascular
diseases [1]. The life-threatening side eﬀects of poor insulin
management expose the need for new therapeutic strategies
to preserve or replenish the functional β-cell mass and
consequently maintain glucose homeostasis. In this scope,
phase II clinical trials performed in patients with recent-
onset T1DM using anti-CD3 monoclonal antibodies that
suppress the immune system showed significant preservation
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of β-cell function for at least 24 months and to decrease
insulin requirements [2]. Despite these beneficial eﬀects, this
intervention alone does not restore normal glucose control
highlighting the need for the development of alternative
therapies aimed at preserving or replacing destroyed β-cells.
In the past 10 years, islet transplantation has gained much
attention as a cell replacement therapy for restoring the
functional β-cell mass. Approximately 400 individuals have
received allogeneic isolated islets since 1999 [3]. Unfortu-
nately, the limited supply of islets from donors cannot meet
the demand imposed by the ever-growing number of T1DM
patients. Furthermore, a major hurdle has been the lack
of durability of islet function resulting in only less than
50% of recipients with insulin independence two years after
transplantation [4]. In addition to side eﬀects produced
by immunosuppression, several posttransplant events, such
as instant blood mediated inflammatory reaction (IBMIR)
and cytokine cascade, seriously aﬀect the functionality
of transplanted islets [5–8]. Nonetheless, the promising
outcome of islet transplantation has prompted the search for
alternative sources of β-cells. One such alternative has been
diﬀerentiation of insulin-producing cells from embryonic
and adult stem/progenitor cells. However, despite the high
number of diﬀerentiation protocols described in the litera-
ture, none published to date have generated by exclusive in
vitro diﬀerentiation suﬃcient numbers of insulin-producing
cells meeting all essential criteria that define a functional β-
cell [9].
A more recent and provocative alternative to cell replace-
ment therapy for the treatment of DM has been the concept
of in vivo regeneration to replenish the loss of β-cell mass.
Basically, the ultimate goal of this strategy is to enhance the
regenerative capacity of the pancreas. Studies in animal mod-
els and in humans have demonstrated that obesity-associated
insulin resistance as well as increased insulin requirements
during pregnancy is matched by a corresponding stimulation
in insulin output through β-cell hyperplasia and hypertrophy
[10]. Studies in the non-obese diabetic (NOD) mouse,
an important animal model of experimental autoimmune
diabetes, have confirmed the importance of β-cell replication
and improved survival under pathophysiological conditions.
It was shown that β-cell replication increases with the
occurrence of islet inflammation during progression of DM.
Nonetheless, by three months mice develop hyperglycemia
as the autoimmune attack counteracts the attempt of β-cells
regeneration by the organism [11]. Of note, in condition
in which autoimmunity and islet inflammation are blunted
using an anti-CD3 immune therapy, newly formed β-cells
derived from preexisting ones are suﬃcient to normal-
ized blood glucose levels [12]. These studies highlight a
fundamental paradigm in the approach to treat DM. A
combinatorial approach in which both regeneration and
resistance to destruction are enhanced will need to be
targeted in order to successfully regain a functional β-cell
mass and maintain normoglycemia. A regenerative approach
to DM is a matter of life and death. In this context, an array
of growth factors and transcription factors have been shown
to be involved in these regulatory pathways, providing an
attractive perspective for the development of new therapeutic
strategies to maintain adequate β-cell mass for stabilization
or even improvement of glucose metabolism in DM patients.
The question is which ones from the ever-growing list of
factors will convey, alone or in combination, the best winning
chance of survival and growth to β-cells? In this context
we have selected 4 candidates, the hepatocyte growth factor
(HGF), the growth inhibitory peptide or glucose-dependent
insulinotropic polypeptide (GIP), the transcription factors
Pax4, and the orphan nuclear liver receptor homolog-1
(LRH-1) as rising stars in the field of β-cell regeneration.
These factors exert several beneficial actions on β-cells
simultaneously such as conferring β-cell protection and
enhancing proliferation. In addition, some of them have been
shown to improve β-cell function under pathophysiological
conditions. Thus, they are very attractive targets for that
combinatorial approach to treat DM, in which β-cell mass
is not only increased but also protected from death. These
four factors could also be utilized in β-cell replacement
therapies as a part of either pre- or postislet transplantation
treatments.
This paper highlights recent advances pinpointing to the
importance of these candidates in β-cell regeneration as well
as to provide insight on how at the molecular level they
merge towards similar targets involved in cell replication
and survival. These may eventually be employed alone or in
combination in an eﬀort to increase islet mass, viability, and
function in patients with DM.
2. The HGF/c-Met Signaling Pathway
HGF is a heterodimeric protein that binds to the tyrosine
kinase receptor c-met. Stimulation of c-met by HGF results
in the activation of several downstream signal transduction
pathways including PI3K/AKT, MAPK, and PKC [13]. Inter-
estingly, HGF was also shown to induce Wnt-independent
nuclear translocation of β-catenin subsequent to met-β-
catenin dissociation in liver cells resulting in cell replica-
tion [14]. In this context, the HGF/c-met axis possesses
potent mitogenic eﬀect on various tissues such as liver,
lung, kidney, spinal cord, heart, and skeletal muscle upon
injury [15, 16]. HGF and c-met are also expressed in the
pancreas, and levels are significantly increased in islets of
gestating mice as well as in cytokine-treated islets. The
latter suggests that the HGF/c-met signaling pathway may
be crucial for islet adaptation in response to metabolic
demands [17, 18]. Consistent with this premise, pancreas-
specific ablation of c-met increased sensitivity of islets
to cytokine-induced apoptosis in vitro through increased
NF-κB signaling and nitric oxide production. Treatment
of c-met null animals with multiple low doses of STZ,
a β-cell specific diabetogenic agent, resulted in increased
islet chemokine secretion, higher degree of insulitis, and
increased β-cell apoptosis as compared to that observed in
wild type treated littermates. These inflammation features
combined with β-cell death led to a reduced β-cell mass and
higher incidence of hyperglycemia [18]. Similarly, pregnant
mice lacking c-met in the pancreas displayed blunted β-cell
replication with a concomitant increase in cell death leading
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to GDM. This defect was linked to reduced levels of the
prolactin receptor as well as in levels of the transcription
factor FoxM1, two important players in cell proliferation. A
decreased nuclear translocation of STAT5 and upregulation
of the replication inhibitor p27 were also detected in c-
met-ablated islets [17]. These studies clearly identify the
HGF/c-met signaling pathway as an important axis activated
in conditions of metabolic stress in which islets require
increased protection and proliferation. Thus, manipulation
of this pathway may provide a new therapeutic venue for the
treatment of DM. Consistent with this premise, adenoviral-
mediated expression of HGF in nonhuman primate islets
markedly improved function of transplanted islets. Indeed,
only a marginal mass of islets expressing HGF was required
to correct hyperglycemia in NOD-SCID mice as compared
to the number of control islets needed to normalize blood
glucose levels in the same animals. Furthermore, HGF-
expressing grafted islets exhibited less apoptosis [19–21].
Although similar eﬀects need to be established for human
islets, these results are certainly encouraging and validate the
usefulness of HGF for novel regenerative and replacement
DM therapies.
In addition to its eﬀect on proliferation and survival,
HGF in combination with betacellulin was recently shown
to induce in vitro transdiﬀerentiation of pancreatic ductal
endothelial cells (PDECs) into β-cells [22, 23]. Approxi-
mately, 30% of HGF-treated PDEC cells transdiﬀerentiated
into insulin-producing cells. This percentage was increased
to 60% when HGF was used in combination with betacel-
lulin. The phenotype of these newly diﬀerentiated β-cells
was very similar to that of mature β-cells, expressing near
physiological levels of insulin and GLUT2. These cells also
exhibited insulin secretion in response to glucose. Interest-
ingly, transdiﬀerentiation of these PDECs was dependent on
the temporal and sequential expression of key endocrine
development transcription factors such as PDX-1, Ngn3,
NeuroD, and Pax4 [23]. Using specific inhibitors for the
diﬀerent signaling pathways activated in PDECs upon HGF
treatment, Li et al. suggested that HGF induces PDECs diﬀer-
entiation into insulin-producing cells through the PI3K/AKT
cascade [22]. Whether similar transdiﬀerentiation can occur
in vivo remains to be established. The latter will also be
valuable to determine the potential mitogenic side eﬀect
of HGF on PDECs. Indeed, Li et al. found that HGF
increased proliferation of PDEC through activation of the
MEK1/2-ERK1/2 pathway [22]. Thus, the balance between
HGF-mediated proliferation and transdiﬀerentiation into
β-cells should be carefully investigated. Taken together,
recent findings reinforce the value of HGF as a potential
therapeutic agent that can increase islet number, viability,
and functionality, three vital attributes for the treatment of
DM through regenerative medicine.
3. The Incretin GIP
GIP and glucagon-like peptide-1 (GLP-1) are two incretin
hormones produced by the K and L-cells of the intestine,
respectively. These incretins are secreted in response to food
intake and potentiate glucose-induced insulin secretion from
pancreatic β-cells in healthy individuals. Nonetheless, both
peptides are rapidly degraded by dipeptidyl peptidase IV
(DPP-IV) [24]. In view of their insulinotropic properties,
major eﬀorts have focused on developing either mimetics of
incretins, which are resistant to DPP-IV or inhibitors of DPP-
IV. Historically, GIP was rapidly discarded as a therapeutic
target due to its impaired insulinotropic eﬀect in T2DM
patients. Nonetheless, recent evidence suggests that GIP may
be a promising target for the preservation and regeneration
of a functional β-cell mass in DM. Indeed, GIP was shown to
be important for β-cell development as well as postnatal islet
mass expansion and function. Transgenic mice expressing
a dominant negative GIP receptor specifically in pancreatic
β-cells displayed an early disturbance in pancreatic islet
development with a severe reduction in the β-cell mass
with a commensurate increase in α-, δ-, and PP-cells [25].
Adult transgenic animals had reduced number of islets
and β-cells as compared to control littermates. Minimal
postnatal islet expansion occurred due to a reduction in islet
neogenesis. Intriguingly, islet proliferation and apoptosis
were only slightlymodified as compared to control mice [26].
Consistent with altered islet architecture, insulin secretion
was impaired and animals developed early-onset DM [25].
In addition to its profound impact on development, GIP
was also shown to increase mouse islet β-cell survival in
response to high glucose and lipid levels (glucolipotoxicity)
through activation of the PI3K/PKB pathway and downreg-
ulation of the proapoptotic factor Bax [27]. In addition,
GIP stimulated expression levels of the antiapoptotic bcl-2
[28]. Studies using human islets revealed that GIP could par-
tially block cytokine-mediated cell death clearly providing
protective properties to this incretin. Interestingly, this anti-
apoptotic eﬀect appeared to be conveyed by GIP-mediated
increases in islet osteopontin [29]. Consistent with these in
vitro data, administration of a DPP-IV-resistant analogue of
GIP to rats blunted the adverse eﬀects of streptozotocin on
islet β-cell destruction and development of hyperglycemia.
Furthermore, the GIP analogue also preserved β-cell mass in
ZDF rats through decreased apoptosis [30]. In vitro, GIP was
shown to stimulate proliferation of newborn rat islet β-cells,
a mechanism potentially involving the activation of cyclin D1
[31]. Thus, GIP analogues resistant to DPP-4 cleavage may
represent a promising new class of therapeutic compounds
with properties to enhance as well as to preserve the critical
β-cell mass required to maintain normoglycemia in DM
patients.
4. The Islet-Enriched Transcription Factor Pax4
Pax genes encode a family of transcription factors that are key
regulators of tissue development and cellular diﬀerentiation
in embryos acting to promote cell proliferation, migration
and survival. In the pancreas, Pax4 was shown to be essential
for the generation of islet cell progenitors and subsequent
β- and δ-cell maturation during embryogenesis [32, 33].
Although detectable, the expression of the transcription
factor in adult islet β-cells was found to be low as compared
to its embryonic expression [34, 35]. In contrast, aberrantly
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high expression levels of Pax4 were detected in human
insulinomas as well as lymphomas [36, 37]. A distinctive
attribute of Pax4 is that mutations and polymorphisms in
this gene have been associated with both T1DM and T2DM
in several ethnic populations [38]. Taken together, these
unique characteristics strongly indicate a vital role of Pax4
not only during development but also in survival and/or
maintenance of cell mass in mature islets. Consistent with
the notion that Pax4 expression may be important for β-
cell adaptation, in vitro studies performed in human islets
demonstrated that glucose as well as growth factors such
as betacellulin, activin A, and GLP-1 increased Pax4 mRNA
levels [35]. Furthermore, Pax4 levels were also found elevated
in islets derived from T2DM patients correlating with hyper-
glycaemia, indicating a potential adaptation of β-cell mass
in response to insulin resistance [35]. Ectopic expression
of mouse Pax4 in either human or rat islets as well as in
the mouse insulinoma MIN6 cell line conferred protection
against cytokine-mediated cell death and promoted islet cell
proliferation [34, 39]. Interestingly, a diabetes-linked mutant
variant R121W identified in the Japanese population was less
eﬃcient in protecting human islets against cytokines [34].
Supporting the role of Pax4 in survival/maintenance of β-
cell mass, repression of Pax4 in the rat insulinoma INS-
1E cell line and in hematologic cell lines that express high
levels of the transcription factor provoked apoptosis [36, 40].
More recently, conditional overexpression of Pax4 in adult
β-cells was shown to protect transgenic animals against STZ-
induced hyperglycemia and isolated islets against cytokines,
while animals expressing the mutant R121W variant were
susceptible to developing hyperglycemia and β-cell death by
both treatments. These antiapoptotic eﬀects were shown to
be mediated by increased expression of the antiapoptotic
gene bcl-2 and downregulation of the NF-κB pathway. Con-
sistent with a role for Pax4 in β-cell replication, the cell cycle-
dependent kinase, cdk4 was increased in Pax4 overexpressing
islets and promoted the proliferation of a Pdx1-positive
subpopulation [41]. Together, these studies suggest that
Pax4 functions as a survival and proliferation gene allowing
mature islets to expand in response to physiological cues.
An additional astonishing regenerative property of Pax4
that was recently uncovered is its capacity to reprogram α-
cells to β-cells. Indeed, using an elegant Cre/LoxP approach
in which the Cre recombinase was under the transcriptional
control of the glucagon gene promoter, Collombat et al.
showed that forced expression of Pax4 in developing α-
cells induced a phenotypic switch towards β-cells. This was
accompanied by an increase in islet size and in the quantity
of insulin positive cells with a concomitant decrease in α-
cell number. Remarkably, the conversion and thus decrease
in the α-cell population resulted in neogenesis of new α-
cells from duct-associated progenitor cells in adult animals.
Nonetheless, these new replenished α-cells were continu-
ously converted to β-cells due to Pax4 ectopic expression.
Regeneration of the β-cell mass by aberrant expression of
Pax4 in α-cell was able to transiently rescue hyperglycemia in
young animals rendered diabetic by chemical treatment [42].
The mechanism by which Pax4 achieves reprogramming of
α- to β-cells is thought to occur through the antagonistic
eﬀect of Pax4 on Arx, a key transcription factor involved in α-
cell lineage commitment and subsequent mature function. It
will be of great interest to determine whether the conditional
and selective expression of Pax4 in mature α-cells using an
inducible and reversible system will promote conversion to
β-cells and whether repression of Pax4 will revert these cells
back to α-cells. In this context, two independent studies have
recently provided elegant evidence for the replenishment of
the β-cell mass through α-cells conversion subsequent to
severe pancreatic damage. Using an animal model in which
the diphtheria toxin receptor was expressed specifically in
β-cells, Thorel and colleagues obtained a near total β-cell
ablation through administering of diphtheria toxin (DT)
while maintaining all other endocrine cells intact [43]. This
approach allowed the investigators to examine the contri-
bution of remaining endocrine cell subtypes to putative β-
cell regeneration. Using an inducible, tamoxifen-dependent
Cre/Lox-based lineage tracing system, the authors concluded
that following β-cell ablation, regeneration stemmed pre-
dominantly from a non-β-cell source. The irreversible label-
ing of α-cells showed that under approximately 99%β-cell
loss, bihormonal cells expressing both insulin and glucagon
were observed which ultimately generated single-hormone
insulin positive cells. It is worth noting that the severity of the
damage greatly influenced α-to-β-cell conversion, since this
transdiﬀerentiation was not observed under approximately
95% destruction. Why such reprogramming mechanisms
are not observed by slightly lower amounts of β-cell loss
remains to be understood. Consistent with these results, an
independent study also claims to have observed pancreatic
β-cell neogenesis by direct conversion of mature α-cells
subsequent to pancreatic duct ligation (PDL) coupled to
alloxan treatment. In this study, an astonishingly rapid α-
to β-cell transdiﬀerentiation was detected, resulting in the
formation of new islets within 2 weeks. Nonetheless, treated
mice never achieved normoglycemia. The authors proposed
that the latter was most likely due to the profound and
continuing inflammation and disruption of normal organ
homeostasis that occurred following PDL/alloxan treatment
[44]. An alternatively explanation which is not addressed
could also be that the newly formed insulin-positive cells
are nonfunctional β-cells. Although this study substantiates
the work of Thorel and colleagues [43], no genetic lineage-
tracing experiments were performed to clearly ascertain that
α-cells were the predominant source of new β-cells. In this
context, it is intriguing that although there was a greater rate
of β-cell replication as compared to α-cell replication (6%
versus 5% at 7 days after treatment), the authors excluded
these residual β-cells as a potential source for regeneration
in this particular injury model. Thus, whether a bona fide α-
to β-cell reprogramming occurs in the PDL/alloxan model
remains to be clearly established, and key factors driving this
process have yet to be identified. In this context, determining
whether Pax4 is implicated in the conversion of mature α to
β-cells in these in vivomodels of β-cell regeneration will be of
great interest. Indeed, a recent study has challenged the role
of Pax4 on the transdiﬀerentiation of α- to β-cells, pointing
to Men1/Menin as the main factor driving this process. In
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this case, it was found that specific ablation of Men1 in α-
cells triggered reprogramming towards β-cells with the sub-
sequent development of insulinoma [45]. Although Men1
could have a role in α-cell plasticity, it is currently diﬃcult to
discriminate whether this is a specific eﬀect or only related to
tumorigenesis. Independently, the identification of signaling
molecules that trigger reprogramming of α-cells may oﬀer
new therapeutic tools for the treatment of DM.
Taken together, Pax4 certainly fulfills all requirements
as a first-class target candidate for the development of in-
novative β-cell regenerative therapies for the treatment of
DM. Indeed Pax4 (1) increases β-cell survival in response
to metabolic stresses (2) stimulates proliferation, and (3)
promotes conversion of α- to β-cells. Nonetheless, it is
important to note that long-term expression of Pax4 may
not be beneficial for β-cells as the cells revert to a progenitor
phenotype thereby losing their capacity to secrete insulin in
response to glucose [41]. Thus, identifying small molecules
or factors that transiently activate Pax4 in either α- or β-
cells will be instrumental for the development of novel
antidiabetic treatment.
5. The (Orphan) Nuclear Receptor LRH-1
LRH-1 is a member of the NR5A2 subfamily of nuclear
receptors which is predominantly expressed in the liver,
[46], exocrine pancreas [47, 48], intestine [49], and ovaries
[50]. In these tissues, LRH-1 regulates expression of genes
involved in cholesterol and bile acid metabolism as well as
steroidogenesis [51]. LRH-1 was also found to attenuate the
acute phase response (APR) that is triggered in response to
inflammatory cytokine signaling in the liver thereby prevent-
ing cell death [52]. Recently, human, mouse, and rat islets
were shown to express LRH-1. More importantly, LRH-1 was
found to partially convey the beneficial eﬀects of estrogens
on β-cell survival. Pharmacological studies using activators
as well as inhibitors of estrogen receptors revealed that LRH-
1 expression was predominantly induced through activation
of Estrogen Receptor (ER)α. Repression of LRH-1 by RNA
interference abrogated the protective eﬀect conveyed by
estrogen on islets against cytokines. Furthermore, previous
studies have demonstrated that aberrant expression of LRH-
1 is associated with the growth of intestinal tumors as well
as with the proliferation of pancreatic and hepatic cell lines
[49, 53]. However, the latter finding is in disagreement with
adenoviral-mediated overexpression of LRH-1 in human
islets, which did not increase β-cell proliferation [54]. LRH-1
appears to promote cell replication by stimulating expression
of cyclinD1 and E1, a process that involves a crosstalk with
the β-catenin/Tcf4 signaling pathway [49]. Low levels of β-
catenin in mature islet may provide an explanation for the
lack of LRH-1 eﬀect on cell proliferation [54]. In contrast,
LRH-1 was found to confer protection against cytokine-
and STZ-induced apoptosis. The steroidogenic enzymes
CYP11A1 and CYP11B1 that are involved in glucocorticoid
biosynthesis were increased in transduced islets. As these
steroids are potent immunosuppressors, glucocorticoids in a
paracrine manner may mediate the protective eﬀect of LRH-
1 [54]. Of note, glucocorticoids were shown to be diabeto-
genic and to hamper islet function in vivo [55, 56]. These
findings led to their exclusion from immunosuppressive
regimens given to patients subsequent to islet transplantation
[7]. However, a recent study demonstrated that exogenous
glucocorticoids have potent anti-inflammatory properties
on human islets. Furthermore, although glucocorticoid-
treated human islets exhibited a rapid reduction in glucose-
induced insulin secretion observed within 24 hours, these
islets performed considerably better than control islets
in long-term culture [57]. Consistent with the beneficial
impact of glucocorticoids on islet integrity, a recent study
demonstrated that optimal elevation of glucocorticoids in β-
cells was a compensatory mechanism that prevented high-fat
diet-induced β-cell failure [58]. Thus, in contrast to previous
beliefs, low levels of glucocorticoids generated endogenously
by factors such as LRH-1 may be advantageous to preserve
β-cells against metabolic aggressions.
Given the importance of LRH-1 in regulating several
key metabolic pathways including lipid metabolism as well
as in modulating cellular homeostasis (cell proliferation
and survival), attempts to regulate its activity could be of
therapeutic value for the treatment of DM. In this context,
although LRH-1 is considered an orphan receptor that pos-
sesses constitutive activity, small endogenous phospholipid
were shown to bind the ligand pocket domain of the protein
and to increase its activity [59]. Taking advantage of this
knowledge, a recent study demonstrated that administration
of the phospholipids dilauroyl phosphatidylcholine (DLPC)
decreased hepatic steatosis and improved glucose home-
ostasis in two mouse models of insulin resistance. These
beneficial eﬀects were predominantly mediated through
increased hepatic LRH-1 activity. These results have led to
a pilot human clinical study in USA to explore the eﬀects
of DLPC in pre-T2DM patients [60]. In parallel, it will be
of interest to determine whether small molecule agonists of
LRH-1 recently developed by Whitby and colleagues [61]
can protect human islets against stressed-induced cell death
and prevent onset of hyperglycemia in animal models of
experimental autoimmune diabetes. The anti-inflammatory
properties combined with the prosurvival eﬀects of LRH-1
highlight the immense potential of this newcomer and rising
star target for the treatment of both T1DM and T2DM.
6. Perspectives
DM is now considered one of the most common noncom-
municable diseases in the world causing 5% of all deaths per
year. Regardless of its aetiology, the end point of DM is β-
cell death. Therefore, new therapies should aim at restraining
β-cell death and promote β-cell performance in patients in
order to improve blood glucose without treatment-derived
side eﬀects. Currently, a potpourri of growth factors and
transcription factors have been highlighted for their ability
to preserve and/or increase β cell mass. The hierarchy or
specific networks connecting them together and value in
treating diabetic patients are yet to be established. Most
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Figure 1: HGF, Pax4, GIP, and LRH-1 increase β-cell regeneration and preservation. Schematic representation of the putative interactions
among HGF, GIP, Pax4, and LRH-1 that impact β-cell survival and expansion. (a) These factors regulate common pathways and targets such
as NF-κB and bcl-2 that exert beneficial eﬀects on β-cells. (b) HGF and Pax4 promote transdiﬀerentiation from other pancreatic cells to
β-cells in addition to enhancing β-cell survival and function.
likely these factors will have to be used in combination
to optimize viability of β-cells as well as to increase the
replication capacity. Nonetheless, as current published data
point to a declining capacity of β-cells to replicate with
age [62, 63], eﬀorts should focus on characterizing factors
capable of preserving and protecting the β-cell cell mass
under pathophysiological situations. In this context, HGF,
GIP, Pax4, and LRH-1 in various permutations may hold
the key to a successful regenerative therapy applied to
DM. Indeed, these factors appear to either complement
or share common signaling pathways and downstream
targets resulting in increase islet viability and performance
(Figure 1). For instance, HGF and Pax4 both inhibit the NF-
κB pathway leading to increased β-cell survival. Similarly,
GIP and Pax4 enhance expression of the antiapoptotic gene
bcl-2. As we have previously demonstrated that GLP-1
stimulates Pax4 expression in human islets [35], it will be
of interest to determine whether GIP also increases Pax4
expression resulting in the downstream activation of the bcl-
2 gene. Consistent with this possibility, both GIP-mediated
β-cell protection and GLP-1-conveyed increases in Pax4
are relayed by the PI3K signaling pathway [27, 35]. HGF
combined with small LRH-1 agonists may be suﬃcient to
stimulate human islet β-cell expansion. Indeed, HGF was
shown to provoke the release of β-catenin from c-met with
its subsequent translocation to the nuclei [14]. Accumulation
of nuclear β-catenin may reach suﬃciently high levels to
interact with LRH-1 and activate downstream target gene
such as cycd1 [49]. In addition, both LRH-1 and HGF
have been shown to decrease inflammation, an important
mediator of cell death in DM [18, 54]. Finally, HGF and Pax4
have the additional property to promote transdiﬀerentiation
of PDECs and α-cells into β-cells. This could be extremely
beneficial as an alternative method to replenish a functional
β-cell mass due to the limited replication capacity of β-
cells. It is also interesting to note that α-cells appear less
susceptible to autoimmune attack with an apparent increase
in the number of α-cells in Type 2 diabetic subjects.
In this context, a combined HGF/c-met, Pax4, and GIP
therapy could be optimal: β-cell protection with increased
proliferation as well as the generation of new β-cells from α-
cells. Nonetheless one important consideration to take into
account is that regeneration and tissue responses are very
diﬀerent under various contexts, such as the severity of the
injury or the age of disease onset. Furthermore, vigilance is
of essence also to restrain the potential deregulated cellular
growth when using such factors. Thus, to be successful,
this type of regenerative therapy requires intervention at a
threshold point at which β-cells are still present and that the
pancreas retains some regenerative plasticity. Alternatively,
these factors could also be useful for optimizing islet
transplantation. Indeed, increased islet isolation yields and
Journal of Transplantation 7
posttransplantation islet performance and survival could be
feasible using a combination of HGF, GIP, Pax4, and LRH-
1. The latter approach would reduce the number of islets
required for transplantation and improve long-term islet
function.
Islet β-cell regeneration is a fast moving field in which
great advances can be achieved in the next few years with
promising potential for the treatment of DM. The next step
is to elucidate the molecular mechanisms that intertwine
HGF, GIP, Pax4, and LRH-1 together in promoting survival
and rejuvenation of islet cells. These studies will most likely
highlight additional factors that may become novel targets
for regenerative therapies.
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